Benefit of an Early Invasive Management Strategy in Women With Acute Coronary Syndromes

Abstract
Studies of acute coronary syndromes (ACSs) have suggested that the sex of patients influences both patient outcomes and the response to recent advances in medical and invasive therapies for ACS.1-8 In particular, no benefit of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition in women with ACS was seen in a meta-analysis, while invasive management of ACS led to worsened outcomes for women in the FRISC II (Fragmin and Revascularization during Instability in Coronary artery disease II) and RITA 3 (Randomized Intervention Trial of unstable Angina 3) randomized controlled trials6,9,10 but to improved outcomes in a prospective observational study.11 These conflicting data have led to controversy about the role that the sex of patients should play in determining risk and in selecting optimal management strategies.

This publication has 13 references indexed in Scilit: